Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Chicken TNFRSF18

Cat.No. : TNFRSF18-2565C
Product Overview : Recombinant Chicken TNFRSF18 full length or partial length protein was expressed.
  • Specification
  • Gene Information
  • Related Products
Source : Mammalian Cells
Species : Chicken
Tag : His
Form : Liquid or lyophilized powder
Endotoxin : < 1.0 eu per μg of the protein as determined by the LAL method.
Purity : >80%
Notes : This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
Storage : Store it at +4 oC for short term. For long term storage, store it at -20 oC~-80 oC.
Storage Buffer : PBS buffer
Gene Name : TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Gallus gallus (chicken) ]
Official Symbol : TNFRSF18
Gene ID : 419424
Protein Refseq : NP_001026045
UniProt ID : Q5ZMR1

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment? 12/20/2022

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment? 06/29/2019

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies? 12/30/2018

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes? 05/05/2018

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies? 05/20/2016

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.

Customer Reviews (3)

Write a review
Reviews
12/20/2021

    This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

    03/05/2020

      Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

      10/01/2017

        The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

        Ask a Question for All TNFRSF18 Products

        Required fields are marked with *

        My Review for All TNFRSF18 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends